Study shows potential of gene-editing liver resident T cells to treat hepatic tumors
27 November 2018
A recent study by the Maini group shows the potential of gene-editing liver resident T cells to treat hepatic tumors and viral infections.
Work on the paper, 'Molecular recalibration of PD-1+ antigen-specific T cells from blood and liver', was carried out by Itziar Otano who joined the Maini lab from Universidad de Navarra in Pamplona, Spain to work as a post-doc, funded by EASL and the Wellcome Trust.
For the final part of this project, Itziar worked in the labs of Andrea Pavesi and Antonio Bertoletti in Singapore to test genetically engineered T cells in their 3D microfluidic model of HBV-related liver cancer.
- Read the paper: Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver (Molecular Therapy Journal)
- Profile: Professor Mala Maini
- Website: Maini Group
- Credit: 'Hepatitis B virions with Dane particles', Dr Erskine Palmer, CDC via Flickr